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Background: Gastroesophageal reflux (GER) in adults with cystic fibrosis (CF) is poorly characterized. This study examines the frequency and
predictors of GER symptoms and their relationship to lung function in adults with CF.
Methods: Cross-sectional study of adults at the University of Minnesota CF Clinic using two validated self report surveys: The Mayo GER
questionnaire and the GERD Symptom Assessment Scale (GSAS).
Results: Of 274 invited patients, 201 (73%) completed the surveys and 173 performed spirometry at the same visit. Frequent symptoms (at least
weekly) were reported by 24% of the patients and an additional 39% experienced occasional symptoms. Heartburn, acid regurgitation and
dysphagia were the most common symptoms and 18% reported that GER symptoms worsened their respiratory condition. Females and patients
reporting weight loss had more symptoms (mean GSAS symptom score 4.9 vs. 4.0, p=0.025 and 5.3 vs. 4.2, p=0.04) and more severe symptoms
(mean GSAS distress score 5.6 vs. 3.8, p=0.005 and 6.8 vs. 4.0, p=0.01) compared to males and those who did not report weight loss. Patients on
acid suppression (n=122, 61%) continued to report heartburn (n=80, 66%) and acid regurgitation (n=47, 23%). GER symptoms and severity of
symptoms were not predictive of FEV1 or FVC.
Conclusions: GER symptoms were present in a majority of patients. Females and patients with weight loss require special attention to their GER
symptoms. Many patients on acid suppression continued to be report symptoms.
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Gastroesophageal reflux disease (GERD) has long been
suspected of exacerbating a variety of respiratory diseases.
Asthmatics, lung transplant recipients, and patients with chronic
obstructive pulmonary disease (COPD) have a higher preva-
lence of GERD than the general population [1,2]. Moreover, a
number of studies suggest that treatment of GERD can improve
the course of asthma [3] and reduce the risk of chronic rejection
following lung transplantation [4]. Over the last 30 years,
advances in care have resulted in a growing population of adults
with cystic fibrosis (CF) [5], but the impact of GERD on this
population remains poorly understood. GERD is more common
in infants and children with CF than in the general population
[6–9], but there are few comparable studies in adults [10,11].
Furthermore, evidence that GERD adversely impacts lung
function in CF is limited [12]. However, GERD can complicate
malnutrition in CF [13,14], and the possibility that acid
blockade improves the clinical course of CF has prompted
many physicians to aggressively treat GER symptoms.
Validated questionnaires are used to assess GER symptoms
in the general population. The purpose of this study is to
determine the frequency and predictors of GER symptoms in
adults with CF using validated questionnaires, and to examine
the relationship between reflux symptoms and lung function.
2. Methods
2.1. Study population
This is a prospective, cross-sectional study of CF patients
attending the adult program of the Minnesota CF Center. The
study was conducted between May, 2004 and May, 2005.
Inclusion criteria were age N18 years, a diagnosis of CF by
sweat chloride testing or genotyping, and ability to read English
above a 6th grade level. Questionnaires were administered in
conjunction with CF clinic visits. Many but not all patients
performed routine spirometry in association with their clinic
visit. In general those patients with recent sinus surgery or who
were being seen for non-pulmonary issues did not perform
spirometry in association with their clinic visit. Hospitalized
patients and those with known esophageal pathology were
excluded.
2.2. Survey instruments
Patients completed the modified Mayo GER questionnaire
(GERQ) and the Gastroesophageal Reflux Disease Symptom
Assessment Scale (GSAS). The Mayo GERQ is a validated self-
administered questionnaire [15] that has been used in a large
population based survey of GER symptoms [16] as well as to
study GER in patients with COPD [2]. The questionnaire asks
about 7 symptoms experienced during the preceding 12 months:
heartburn, acid regurgitation, trouble swallowing, chronic
cough, lump in throat, belching, and hiccups. The instrument
characterizes each symptom by its timing, severity and
relationship to respiratory symptoms.The GSAS is a validated self-administered questionnaire that
asks patients to report the presence, frequency, and distress
associated with 15 symptoms during the preceding week [17].
The instrument yields a symptom score (range 0–15) and a
distress score (range 0–45). The symptom score is based on the
presence or absence of 15 symptoms: heartburn, chest pressure
or discomfort, food coming back into the mouth, an acidic or
sour taste in the mouth, frequent stomach gurgling, pressure or a
lump in the throat, nausea, burning throat pain, bloating,
belching, flatulence, early satiety, halitosis, cough, and
hoarseness. The distress score is based upon the degree of
distress caused by each of the aforementioned symptoms on a
scale from 0 to 3 (not at all, somewhat, quite a bit, and very
much).
2.3. Study protocol
The study and all survey materials were approved by the
Institutional Review Board of the University of Minnesota.
Subjects were recruited and completed the questionnaires in
conjunction with their routine CF clinic visit. Incomplete
surveys, defined as lacking responses to 3 or more items on the
GSAS or missing two or more responses to symptom questions
or two or more demographic items on the Mayo GERQ, were
excluded. Patient height, weight, pulmonary function tests at the
time of the clinic visit, diagnosis of CF related diabetes (CFRD)
by a diabetologist, pancreatic enzyme use, and CF genotype
data were obtained from the Minnesota CF Database and chart
review.
2.4. Statistical analysis
Comparisons of continuous variables between two groups
were assessed using t-tests (Minitab software, Minitab Inc. State
College, PA). Associations between continuous variables were
compared using Pearson's correlation coefficient. Because
cough is present nearly universally in CF patients, we calculated
correlations between GSAS scores and Mayo responses with,
and without, cough included in calculations of GSAS scores.
Chi-square tests were used to analyze categorical variables.
Linear regression analysis was performed to investigate for
possible associations between GER symptoms, GSAS symptom
and distress scores and patient characteristics such as age, sex,
BMI, presence of ΔF508 genotype, NSAID use, pancreatic
enzyme use, diagnosis of CFRD and FEV1 and FVC.
Subgroups for severity of pulmonary disease were based on
percent predicted FEV1 as previously reported by the Cystic
Fibrosis Foundation Patient Registry [5]. Statistical significance
was defined as p value b0.05.
3. Results
3.1. Participants
Of the 431 CF patients registered at the University of
Minnesota CF center, 274 (64%) were invited to participate in
the study.Wewere unable to reach the remainder of the patients in
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invited 204 (74%) completed the surveys, 41 (15%) did not return
the surveys, and 29 (11%) declined participation. Three
incomplete surveys were excluded from analysis. No patients
were excluded due to the presence of co-existing esophageal
pathology.Of the 201 patientswho constitute our study group 109
(54%) were male, mean age (range), 31.4 (18–64) and BMI
(range), 22.8 (15.8–30.8). Of these patients, 179 (89.5%) were
taking pancreatic enzymes and 22 (11%) had CF related diabetes.
Spirometry was performed in 174 (86%) in conjunction with
completing the surveys with amean FEV1 of 68.9%. Based on the
CF foundation criteria 47(27%) had a normal FEV1 (N 90%), 34
(20%) had a mildly abnormal FEV1 (70–89%), 57 (33%) had a
moderate reduction in the FEV1 (40–69%) and 35(20%) had a
severe reduction in the FEV1 (b40%). Genotype data was
available in 158(79%); 95(60%) homozygous for ΔF508 and 51
(32%) heterozygous for ΔF508.3.2. Prevalence and severity of symptoms
From the Mayo GERQ, 126 patients (63%) reported at least
one GER symptom.
The most commonly reported symptoms were heartburn
(53%, n=106), acid regurgitation (33%, n=68) and dysphagia
(18%, n=36). Frequent symptoms, defined as experienced at
least weekly [16] were reported by 24% of all patients (n=48).
More specifically this was reported by 39% (n=41) of those
with heartburn, 25% (n=17) of those with acid regurgitation
and 36% (n=13) of those with dysphagia. When patients with
GER symptoms (n=126) were asked about the impact on their
respiratory condition, 29% (n=36) reported that their GER
symptoms exacerbated their shortness of breath, increased their
cough, wheezing or inhaler use. Of these patients 53% (n=19)
also reported frequent GER symptoms.Table 2
Predictors of GER symptoms.
Dependant variable Coeff±SD P-value
Covariate a
GSASb symptom score
NSAID use c 1.6±0.47 pb0.001
Female sex 1.1±0.56 p=0.053.3. Predictors of GER symptoms
A significantly greater number of symptoms and distress on
the GSAS scale (Table 1) was found in females and in patients
who regularly used NSAIDs (defined as greater than twice aTable 1
Predictors of GER symptoms.
Females vs.
males
NSAID users vs.
non-users
Weight loss vs.
no weight loss
Mean GSAS a
Symptom score
4.93 vs. 4.05
(p=0.025)
5.40 vs. 4.0
(p=0.003)
5.29 vs. 4.24
(p=0.04)
Mean GSAS
distress score
5.63 vs. 3.75
(p=0.005)
6.0 vs. 3.9
(p=0.008)
6.75 vs. 3.99
(p=0.012)
Presence of acid
reflux
N.S. b 41% vs. 29%
(p=0.045)
N.S.
Percent predicted
FEV1
N.S. N.S. 62% vs. 71%
(p=0.045)
Percent predicted
FVC
N.S. N.S. 82% vs. 91%
(p=0.019)
a Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS).
b Not statistically significant (N.S.).week for at least one month, n=76, 38%). NSAID users also
reported more acid regurgitation than non-users. Among
patients with weight loss (self reported, n=51) there was also
significantly greater symptoms and distress on the GSAS scale.
Spirometry in this group showed the patients with weight loss
also had significantly worse pulmonary disease than those
without weigh loss (Table 1).
Analysis of GER symptoms by age categorizing either by
dichotomizing the patients based on median age (med-
ian=29.6 years) or arbitrary subgroups (18–24, 25–29,
30–39, 40–49 and 50+) did not yield any significant
differences in GSAS scores or report of GER symptoms.
Similar analysis of BMI did not yield any significant
differences in GSAS scores or report of GER symptoms. In
addition patient characteristics such as presence of ΔF508
genotype, pancreatic enzyme use and diagnosis of CFRD did
not produce any differences in GSAS scores or report of GER
symptoms.
Multiple regression analysis identified NSAID use, female
sex, pancreatic enzyme use, and absence of ΔF508 alleles as
significant predictors of GSAS symptom scores, while NSAID
use, female sex, pancreatic enzyme use, weight loss and age
predicted GSAS distress scores, and reporting of regurgitation
and dysphagia (Table 2). None of the covariates were predictive
of reporting of heartburn.
3.4. Treatment of GER symptoms
Gastric acid suppression was common, with 122 patients
(61%) taking proton pump inhibitors (PPI) or histamine-2
receptor antagonists (H2RA) (Table 3). The patients on acid
suppression reported more symptoms and more severe
symptoms on the GSAS as well as more heartburn than patientsPancreatic enzyme use 1.8±0.77 p=0.021
Presence of ΔF508 −0.85±0.39 p=0.029
GSAS distress score b
NSAID use 2.2±0.78 p=0.005
Female sex 2.2±0.94 p=0.021
Heartburn
No significant predictors N/A N/A
Acid regurgitation
Age 0.009±0.004 p=0.05
NSAID use 0.16±0.08 p=0.04
Dysphagia
Pancreatic enzyme use 0.22±0.10 p=0.04
Weight loss d 0.15±0.8 p=0.03
a Linear regression performed with age, sex, BMI, presence of ΔF508
genotype, NSAID use, pancreatic enzyme use, diagnosis of CFRD, FEV1
and FVC as covariates.
b Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS).
c Non Steroidal Anti-inflammatory Drug (NSAID) more than twice weekly.
d Self-reported weight loss.
Table 3
Symptom and spirometry for patients using acid suppressing medications.
No acid
suppression
H2RAb PPI c Both
N (% of CF patients) 79 (39%) 29 (14%) 62 (31%) 31 (15%)
Mean GSAS a symptom score 2.9 5.3 4.9 6.8
Mean GSAS distress score 2.9 5 4.9 8.7
N reporting heartburn (%) 26 (33%) 19 (65%) 36 (58%) 25 (81%)
N reporting acid regurgitation
(%)
20 (25%) 10 (35%) 24 (39%) 13 (42%)
Mean FVC 90.5 % 96.4 % 81.5 % 91.2 %
Mean FEV1 70.5 % 76.6 % 62.5 % 70.4 %
a Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS).
b Patients on Histamine-2 receptor antagonists (H2RAs) in the preceding year
had a worse symptom score (p=0.035) and distress score (p=0.001) than
patients not on acid suppression.
c Patients on proton pump inhibitors (PPI) had a worse symptom score
(pb0.0001) and distress score (p=0.0024) than patients not on acid
suppression. More patients on PPI (p=0.003) and H2RA (p=0.03) reported
heartburn than patients not on acid suppression. Patients on H2RA had a
higher mean FVC (p=0.0033) and mean FEV1 (p=0.023) compared to
those on PPI.
Table 4
Comparison of symptoms based on use of acid suppressing medications.
On acid suppression
and reported
GERDb
On acid suppression
and did not report
GERDc
Not on acid
suppression
N (% of CF
patients)
44 (22%) 78 (39%) 79 (39%)
Mean GSASa
symptom score
7.2 4.5 2.9
Mean GSAS
distress score
7.7 4.9 2.9
Heartburn (%) 32 (73%) 48 (62%) 26 (33%)
Acid
regurgitation (%)
23 (52%) 24 (31%) 20 (25%)
Dysphagia (%) 17 (40%) 9 (12%) 10 (13%)
a Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS).
b Patients who reported a diagnosis of GERD had worse GSAS symptom
scores (pb0.001) and distress scores (p=0.015) and reported more acid
regurgitation (p=0.026) than patients on acid suppression who did not
report a diagnosis of GERD.
c Those on acid suppression who did not report a diagnosis of GERD had
worse GSAS symptom (p=0.01) and distress scores (p=0.02) and reported
more heartburn than those not on acid suppression.
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FVC and FEV1. Of the patients on PPI or H2RA 36% (n=44)
reported the indication for taking their medication as “Gastro-
esophageal reflux disease, GERD, or reflux” (Table 4). Patients
who reported a diagnosis of GERD had significantly more
symptoms than other patients on acid suppression not reporting
GERD as an indication.
Of the 79 patients who were not on gastric acid suppression,
35 (44%) reported GER symptoms with 26 (33%) reporting
heartburn, 20 (25%) with acid regurgitation and 10 (13%) with
dysphagia. Compared to patients on gastric acid suppression,
these patients reported less heartburn (33% vs. 66%, pb0.001)
but there were no significant differences in the report of acid
regurgitation or dysphagia (25% vs. 49% and 13% vs. 21%
respectively). Frequent symptoms (at least weekly) were
reported by 5 (19%) with heartburn, 1(5%) with acid
regurgitation and 3(30%) patients with dysphagia. Among
patients not on gastric acid suppression, there were no
significant differences in spirometry between patients with
and without GER symptoms or with frequent GER symptoms.Table 5
Symptom scores by pulmonary severity–FEV1 percent predicted
a.
Normal
≥90%
Mild
70–89%
Moderate
40–69%
Severe
b40%c
n (%) 47 (27%) 34 (20%) 57 (33%) 35 (20%)
Mean GSASb symptom score 4.8 4.8 4.1 3.9
Mean GSAS distress score 4.6 5.3 4.3 4.3
Heartburn (%) 28 (60%) 14 (41%) 32 (56%) 16 (45%)
Acid regurgitation (%) 17 (36%) 10 (29%) 19 (33%) 15 (43%)
Dysphagia (%) 9 (19%) 5 (15%) 10 (18%) 5 (14%)
a Based on previous classification from Cystic Fibrosis Foundation. Patient
Registry 2002 Annual report. Bethesda, MD: Cystic Fibrosis Foundation,
2003.
b Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS).
c There were no statistically significant differences in symptoms between any
of these four severity groups.3.5. Symptom severity and lung function
Spirometry did not differ significantly between patients
reporting GER symptoms, frequent GER symptoms or no
symptoms on the Mayo GERQ. There were no differences in
spirometry between patients who reported their GER symptoms
exacerbating their pulmonary function and those who did not.
To further examine the relationship between GER symptoms
and lung function, patients were categorized into four groups
based on percent predicted FEV1 (N90%, 70–89%, 40–69%
and b40% as on previous report by Cystic Fibrosis Foundation
[5]) (Table 5). There were no significant differences in GSAS
symptom or distress scores, or prevalence of heartburn, acid
regurgitation or dysphagia symptoms between the four groups.
As expected patients with the most severe pulmonary disease(FEV1b40%) were significantly older (vs. FEV1 N90%, 28.0
vs. 36.8, p=0.03), but BMI, ΔF508 genotype, CFRD status,
and pancreatic enzyme use did not differ between groups.4. Discussion
This study is a survey based cross-sectional study of GER
symptoms in adults with CF at a single CF center. Most of our
patients (63%) had GER symptoms and almost a quarter (24%)
had frequent symptoms. Previous studies [6–9] of both adults
and children with CF have reported a prevalence of GER
symptoms of 25–81%, though they have employed differing
criteria. Two small studies (n=50, n=10) comprised exclu-
sively of adults with CF found a high prevalence (80%–88%) of
GERD by pH probe in patients with GER symptoms and
patients awaiting and having received a lung transplant
respectively [10,11]. In a related study Ledson et al.
demonstrated tracheal acidification in adult CF patients with
GERD [18]. In our study there is a disparity between the
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the previously reported 80% of patients with positive pH probe
who may be micro-aspirating. It is possible this is attributable to
the prevalence of acid suppression in our study population.
However, many of our patients on acid suppression continued to
experience significant GER symptoms including heartburn and
acid regurgitation (Table 3). Another important consideration is
that GERD can be clinically silent, as a recent investigation
found silent GERD in a third of studied CF patients [10].
Neither frequency nor severity of GER symptoms were a
primary predictor of severity of lung disease in our study
population. Subjectively, some patients (18%) found their GER
symptoms to exacerbate their respiratory symptoms. The
European Epidemiologic Registry of Cystic Fibrosis found a
“history of GER” was associated with a 5 to 10% lower percent
predicted FEV1 [19]. Although the registry does not supply a
definition for “a history of GER”, the chronic nature of their
findings suggests that the impact of GER on lung function and
spirometry may occur over time and may not be reflected in
evaluation of spirometry from a single time point.
There is no clear mechanism why females with CF have more
frequent and severe GER symptoms. Investigating GER
symptoms in healthy young adults (mean age 18 years) diagnosed
with GER in childhood El-Serag et al. found oral contraception to
be the major risk factor for those on maintained on antireflux
therapy [20]. Oral contraception is reported to be used as
commonly in the CF as the general population [21]. Contracep-
tion was not investigated as a specific risk factor in our study
however in the year prior to the study a survey of our post-
menarchal female CF patients (n=113) over the age of 14, mean
age 27.6 (±9.1) years showed that 67 (59%) of the women were
not using any form of birth control (personal communication, Dr.
Joanne Billings). Females with CF do have decreased survival
relative to males [22], and this warrants further investigation of
GERD in females with CF to determine if there is any impact on
survival. Patients withweight loss were found to haveworse GER
symptoms as well as lung function. This is another sub-group that
should continue to receive attention as GER has been shown to
complicate malnutrition in CF [13,14] and because of the strong
links between nutrition and survival in CF [5].
Many of our patients were taking a PPI, H2RA or both at the
time of survey completion. The patients not reporting GERD as
an indication for acid suppression reflect the common practice
in our center to use acid blockade to enhance pancreatic enzyme
efficiency. A third of patients who reported taking acid
suppression for treatment of GERD had persistent symptoms,
in fact significantly more than patients on acid suppression for
other indications. Also of concern was the number of patients on
acid suppression who continued to experience acid regurgita-
tion and heartburn. This calls to question the response of adults
with CF to PPIs and H2RAs at the current recommended doses.
It may be that gastric acid suppression is inadequate to relieve
GER symptoms and that fundoplication may be of more
therapeutic value because of bilious or non-acid reflux [23].
Blondeau et al. have investigated the relationship between
airway and esophageal symptoms, the role of acid versus non-
acid reflux and aspiration in both children and adults [24,25].While acid and alkaline reflux can occur and bile acids have
been demonstrated in saliva of individuals with CF a causal
relationship or particular treatment methodologies have yet to
be determined.
Regression analysis identified several other predictors of
GER symptoms that did not show statistically significant
differences in univariate analysis including NSAID and
pancreatic enzyme use as well as absence of the ΔF508
genotype. Other factors such as age, BMI, CFRD were not
found to be predictive of GER symptoms. It is possible that the
ΔF508 genotype lacks GER as a frequent manifestation and
other alleles may predispose to GER. Our sample size limited
the study of specific alleles other than ΔF508. Blondeau et al.
however reported bile acids in the saliva and bronchial lavage of
patients homozygous for ΔF508 exclusively [25].
Our study is limited in that it is a cross-sectional study and
many of our patients were on acid suppression at the time of
survey. However, our sample is representative of what providers
see in their day-to-day care for adults with CF. Comparison to a
control population of age and gender matched normal adults or
patients with other pulmonary disorders would be ideal but
difficult to achieve as other respiratory disorders do not share the
same natural history as CF. Despite these short falls our goal was
to characterize GER symptoms rather than compare prevalence
between CF patients and this was achieved. We were unable to
recruit all of the patients registered in our center to participate in
our study. It is possible that there is a selection bias and those
patients with more severe diseases were more likely captured
during recruitment from clinic. However, spirometry results do
indicate an equitable distribution of disease severity. As with any
self report instrument, recall bias may affect responses, although
both instruments have been validated by specialists. The two sub
groups, females and patients with weight loss, both with
associations with decreased survival, have a higher symptom
burden clearly indicating future studies should focus on females
and patients with weight loss. Persistence of symptoms on acid
suppression, previously reported rates of silent reflux and our
finding of the disparity between prevalence of GER symptoms
and the prevalence of GERD by pH probe all suggests that the
mechanism and treatment of GER symptoms in patients with CF
requires further investigation. Our results indicate that GER
symptoms should not be implied as a primary predictor for the
severity of lung disease but the literature does suggest an impact
on lung function over time.References
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